line

Press releases 2010

  • 12/16/2010
    Ad-hoc: Biofrontera received official review of its drug approval dossier for BF-200 ALA

  • 10/20/2010
    Belixos® sales commence in Middle East and North African countries (MENA)

  • 10/6/2010
    Biofrontera’s BF-200 ALA selected by Windhover as worldwide TOP-10 drug development project available for partnering

  • 9/29/2010
    BF-200 ALA drug approval dossier validated

  • 9/3/2010
    Ad-hoc: Biofrontera AG closes placement of capital increase

  • 9/1/2010
    Ad-hoc: Biofrontera files European drug application for BF-200 ALA

  • 8/31/2010
    Biofrontera AG reports half-year financial results for 2010

  • 8/13/2010
    Biofrontera received manufacturing and distribution license

  • 8/4/2010
    Ad-hoc: Biofrontera AG decides on capital increase

  • 6/16/2010
    Ad-hoc: Consolidation of Biofrontera shares under a single ISIN

  • 6/10/2010
    Ad-hoc: Biofrontera AG closes placement of capital increase

  • 6/7/2010
    Ad-hoc: Biofrontera AG decides capital increase

  • 4/29/2010
    Biofrontera publishes financial report 2009

  • 3/22/2010
    Biofrontera included in the NRW-MIX50 Index of the Düsseldorf Stock Market

  • 3/18/2010
    Biofrontera closes distribution deal in Arabic countries

  • 2/26/2010
    Biofrontera has published the audited annual statement for 2008

line2